Not Whether, But How: The Path Forward for Clinical AI

Overview Summary

As clinical AI advances, the organizations that benefit most will be those that evaluate and deploy these tools with the same rigor applied to any other clinical intervention. HDAI helps health systems move from reactive analytics to predictive, patient-level intelligence. HealthVision™ pairs deterministic predictive models, built on a published, peer-reviewed methodology and 25 years of longitudinal CMS data, with generative AI that follows strict guardrails: small-question architecture, clinician-designed prompts, and click-through-to-source transparency. Both are embedded directly in the EHR and supported by dedicated clinical transformation, because clinical intelligence only changes outcomes when it reaches the right clinician at the right moment in the care process.

Clinical AI tools are becoming available to health systems and clinicians at an unprecedented pace. Ambient documentation, natural language processing, predictive analytics, and other breakthrough capabilities are touching nearly every aspect of care delivery, requiring important decisions about how to evaluate, adopt, and integrate these tools into routine practice.

Notably, the emergence of tools like OpenAI’s ChatGPT for Clinicians, bolstered by a growing body of research demonstrating LLMs’ capabilities in clinical reasoning, has opened a seminal conversation about how, and in what capacity, AI can support more consistent, earlier clinical decisions. As organizations look to harness these advances, the greatest impact will come from tools built on validated evidence, embedded in clinical workflows, and designed to strengthen clinicians’ judgment at the point of care.

While there is no single playbook for operationalizing clinical AI, health systems can adopt these tools safely and sustainably by bringing structure and intentionality to their evaluation and deployment. This post offers a practical framework for leaders who are ready to move past the question of “should we use AI?” and into the harder, more productive question of how to standardize the evaluation, implementation, and measurement of these tools across their organizations.

A Turning Point for Clinical AI

That question does not have a simple answer, because clinical AI is not a single category; it spans imaging algorithms, predictive models, and generative tools, each with distinct evidence bases, integration requirements, and risk profiles.

On April 23, OpenAI launched ChatGPT for Clinicians, a free tool for verified U.S. physicians, nurse practitioners, physician assistants, and pharmacists, offering access to a frontier model for clinical questions, cited answers from peer-reviewed sources, workflow templates, and CME credits. The demand behind this launch is well-documented: clinician use of ChatGPT has more than doubled in the past year, and major health systems, including Boston Children’s Hospital, Memorial Sloan Kettering, Cedars-Sinai, and HCA Healthcare, have adopted the enterprise version.

Following the release of ChatGPT for Clinicians, researchers published a study showing that an OpenAI reasoning model performed as well or better than physicians in diagnostic evaluations, including one experiment using real emergency department data. These are promising developments, and they represent something health system leaders should take seriously: capable AI tools are now accessible to their clinical workforce at no cost, whether or not the organization has formally adopted them.

At the same time, the study’s own authors were clear that diagnostic reasoning on text records is one component of clinical care, not the whole of it, and that prospective clinical trials are the necessary next step before these tools inform patient care decisions. As researcher and cardiologist Eric Topol observes in a recent piece, AI tools with years of rigorous evidence—imaging, retinal analysis, polyp detection—have not been widely adopted, while LLMs with far less clinical validation are already in daily use by millions.

Taken together, these developments demonstrate both the progress being made and the need for health systems to be intentional about how they bring these tools into clinical practice: which tools, for which purposes, under what conditions, and measured against what outcomes?

The Need for a Structured Approach

Clinical AI has vast potential to improve care quality, operational efficiency, and decision-making at scale; however, to capture that opportunity, health systems need a structured way to account for the fact that these tools vary enormously in their evidence base, intended use, and clinical risk.

Consider the range. An LLM that helps a clinician draft a referral letter carries a different risk profile than an LLM that suggests a differential diagnosis, and both are different from a predictive model that stratifies a patient population for proactive care management.

Without a framework that accounts for these distinctions, health systems are left making adoption decisions on a case-by-case basis, driven by individual clinician enthusiasm, vendor positioning, or what peer institutions appear to be doing. The result is uneven adoption: some tools embraced too cautiously, others integrated too quickly, and no consistent way to measure whether any of them are delivering on their potential.

Key Considerations for Healthcare Leaders

What does a structured approach look like in practice? Health system leaders evaluating clinical AI tools should consider several foundational questions before deployment and revisit those questions as tools and evidence evolve.

Governance

Organizations need to define who owns the clinical decision when AI is involved, how the tool is monitored for performance drift over time, and what the process is for handling model updates, edge cases, and adverse events. These questions apply equally to LLMs, predictive models, and imaging algorithms, and the answers should be documented, reviewed periodically, and updated as both the tools and their clinical contexts evolve.

Use Case Classification

The single most important step in evaluating any clinical AI tool is to clearly define the intended use case and the level of clinical risk it carries. A tool used for administrative support operates in a different risk tier than a tool used to inform diagnosis, treatment selection, or patient stratification. Health systems should classify each AI application by its intended role and apply evaluation criteria proportional to the clinical stakes involved. The same tool may be appropriate for one use case and premature for another

Clinical Validation

Leaders should ask whether the tool has been validated against longitudinal, population-level data that reflects the complexity and diversity of real clinical environments, using a peer-reviewed, transparent, and reproducible methodology. Models that perform well on curated case vignettes, licensing exams, or simulated scenarios may not perform the same way when exposed to the noise and ambiguity of actual patient records.

Workflow Integration

Health system leaders should evaluate whether the tool embeds into existing clinical workflows at the point of care, or whether it introduces a separate step that clinicians must actively choose to take. Ambulatory physicians already spend nearly six hours on the EHR for every eight hours of scheduled patient time; tools that require clinicians to step outside that environment to access clinical intelligence add friction to a workflow that is already under significant strain. Integration matters because the best clinical intelligence is only useful if it reaches the right clinician at the right moment in the care process.

Transparency and Interpretability

Clinicians need to understand why a tool is surfacing a particular recommendation, risk signal, or diagnosis to act on it with confidence and accountability. Transparency is a prerequisite for governance, for clinician adoption, and for the ability to learn from cases where the AI gets it wrong.

Outcome Measurement

Health systems should define how they will measure whether a tool improves clinical and operational outcomes before they deploy it, not after. Key metrics include operational measures like length of stay, readmission rates, mortality, cost, and whether care decisions are made earlier and more consistently. Establishing this measurement discipline upfront makes it possible to compare tools, justify continued investment, and identify where a tool is underperforming.

Looking Ahead

Clinical AI has reached a level of capability and accessibility that enables health systems to meaningfully improve care delivery, clinical decision-making, and operational performance. Capitalizing on this progress requires building the organizational infrastructure to evaluate, deploy, and measure AI tools with the same rigor applied to any other clinical intervention.

At HDAI, we’ve built our platform around these principles. HealthVision™ pairs deterministic predictive models, built on a published, peer-reviewed methodology and 25 years of longitudinal CMS data, with generative AI that follows strict guardrails: small-question architecture, clinician-designed prompts, and click-through-to-source transparency. Both are embedded directly in the EHR because clinical intelligence that requires a separate step to access doesn’t get used.

For AI to truly equalize access to high-quality care, tools must be purpose-built to complement and amplify the user’s expertise. Structured governance, a valid scientific purpose, robust input, consistent evaluation, transparent reporting, and proven clinical utility are must-have qualities for AI tools in clinical settings. These attributes enable clinical relevance, explainability, workflow compatibility, and quality improvement.

As AI continues to advance, HDAI remains focused on helping health systems move from reactive analytics to predictive, patient-level intelligence, operationalized through evidence-backed models, responsible generative AI, and dedicated clinical transformation support. By surfacing the right insights at the right moment in the care process, we help make AI a standard part of how medicine is practiced.

SHARE

Facebook
Twitter
LinkedIn

Your privacy matters

We believe that an individual’s meaningful control over their own data is as valuable as the data itself. That’s why we are committed to protecting privacy at every turn.
We always:
  • Provide transparency about the information we collect and why we collect it
  • Comply with all applicable privacy rules and regulations
  • Delete personal data from our servers if an individual opts out
We never:
  • Sell data to third parties
  • Share data with third parties besides the primary, explicitly authorized institution
  • Collect data besides what is disclosed
  • Keep personal data for individuals who have opted out

We speak legalese only when we have to, but we do our best to keep it human. Provided below are the full versions of our Privacy Policy and Terms of Service. If you have any questions, don’t hesitate to contact us for clarification.

Scott Cullen MD
Chief Medical Officer

Dr. Scott Cullen has more than two decades of experience advancing clinical innovation, digital transformation, and value-based care. He has held senior leadership roles across health systems and consulting firms where he guided organizations in adopting data-driven, patient-centered care models. As Chief Medical Officer at HDAI, Dr. Cullen helps shape AI-enabled solutions that improve clinical outcomes. His work is grounded in his early career as a practicing physician, a frontline perspective that continues to drive his passion for building technology that empowers clinicians and humanizes healthcare.

Bill Floyd
VP Sales

Bill brings a lifetime of curiosity, discipline, and humor to HDAI. Married for more than 40 years, he is a proud father of three and grandfather to one and shares his home with two dogs—one a rescue—while firmly maintaining a no-cats policy.

An oyster farmer by trade (despite not being an oyster eater or much of a shucker), Bill’s path reflects an appreciation for hard work. He is passionate about business, lifelong improvement, and thoughtful problem-solving, often delivered with a healthy dose of sarcasm.

Raphael Cohen
VP AI and Engineering

With expertise in machine learning, cloud computing, and healthcare, Raphael translates complex technical challenges into practical healthcare solutions. He’s pioneered ML platforms to drive innovations in radiology, pathology, and anesthesia while simultaneously improving operational efficiency and scale. Outside of work, he’s an avid cyclist who regularly participates in the Pan-Mass Challenge, enjoys hiking the White Mountains, and is often found playing guitar. He received a BS in Computer Science and Applied Mathematics from Brandeis University.

Bob Scott
VP Security, Compliance, and IT Operations

Bob has 20 years experience enhancing IT systems and security programs in regulated companies.  He has worked with global enterprises down to 10-person start-ups.  He currently holds both CISSP and CCSP certificates from ISC2.  Bob’s professional passion is negotiating the sweet-spot between Security, Efficiency and Company Resources.  Personally, Bob is a land-locked boatsman who laments every day away from the water and an avid table-top gamer.  He received a BS in Microbiology from Cornell.

Summer Kramer
VP Clinical Programs

Summer is a clinical pharmacist with over 15 years of experience in the healthcare industry, including hospitals, payors, and start-ups. Summer has focused her career on clinical program development and healthcare analytics with a constant drive to improve patient outcomes.

Residing in the pacific northwest, Summer enjoys hiking, camping, sailing, and traveling. She received her PharmD from the University of New Mexico, College of Pharmacy.  

Kevin Sampson
VP Finance

Kevin is a CPA with 25 years of executive and managerial experience in accounting, corporate finance, and operations in a variety of industries including medical device, biotechnology, and pharmaceuticals.

By listening and connecting with people, Kevin understands that accurate timely information is vital for everyone in the healthcare system. He received a BS in Accounting and an MBA in Finance and Entrepreneurial Studies from Babson College.

Paul Manberg
VP Clinical and Regulatory Affairs

Paul is an innovative, pragmatic leader with over 40 years’ experience in the medical device and pharmaceutical industries. He has directed clinical trial programs and regulatory activities supporting the successful market introduction of numerous impactful products. He spends his leisure time on the Outer Banks of North Carolina, body surfing and fishing. He received a PhD in pharmacology from The University of North Carolina School of Medicine.

Scott Greenwald
Chief Scientist

With over 25 years’ experience in healthcare research and innovation, Scott is an unprecedented leader in his field, focusing on improved care for everyone. He is an author of over 10 US Patents and over 100 peer-reviewed abstracts and manuscripts. While he’s not immersed in research, you’ll find him playing a mean round of mini golf. He received a PhD in Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology (HST).

Josh Gray VP Analytic Services

Josh has 30 years’ experience in healthcare, including The Advisory Board Company, athenahealth, and Boston Consulting Group. Across his career, he has used a wide range of conventional and unconventional data sources to understand and teach the keys to top performance among the nation’s most innovative health systems and physician groups. Josh enjoys music, hiking, traveling, and watching his daughter take part in synchronized skating competitions. He received an MBA from The Wharton School at the University of Pennsylvania and an undergraduate degree from Brown University.

Carola Endicott
VP Customer Engagement, Marketing

Carola has 30 years’ experience in healthcare, including HMOs, hospitals, and start-ups. Her knowledge and optimistic outlook in operations and leadership, and her passion for making healthcare workers’ lives easier is what drives her devotion to customer engagement. She received an EdM from Harvard University Graduate School of Education.

David Clain Chief Product Officer

David has vast experience with healthcare customers from his time at The Advisory Board Company and athenahealth. His expertise and passion for statistics, strategy, and innovative analytic insights is unrivaled, as is his devotion to the Duke Blue Devils. Looking for that “aha moment” of positive change is what drives him. He received a BA from Duke University.

Margie Ahearn
VP HR

Margie has 25 years of experience in HR leadership. An avid boater, Margie has received numerous awards for excellence in HR and is always looking for challenges to grow professionally and personally. She graduated with an MBA from Southern New Hampshire University.

Nassib Chamoun
Founder and CEO

Nassib is a data scientist, lover of logistical regression and a serial entrepreneur. Previously, he was Founder and CEO of Aspect Medical Systems, a Nasdaq traded company now owned by Medtronic. Outside of work, he enjoys hosting and honing his cooking skills – specializing in Middle Eastern and outdoor feasts. He received an MS from Boston University.

Phil Devlin
COO

Phil has 30 years of experience in executive leadership. Along his journey he’s made effective and profound change in science. Little known facts about him — he loves traveling with his family, he was in the MD Engineering program at Harvard Medical School and owns 15 patents. He received an MS from Northeastern University.

What guides our culture

1

We are driven to make a profound impact on US healthcare

2

We operate in the best interests of patients and those who serve them

3

We understand and protect patient privacy and health information security

4

We use data science to enhance, but never replace clinical expertise and judgment

5

We are committed to continuous learning and improvement

6

We bring rigor, discipline, and reliability to our work

7

We start with kindness, assuming good intent in others

8

We are committed to building a diverse, inclusive team where all employees feel welcomed and appreciated

9

We are committed to the well-being of our employees and their families

Our vision

We envision a healthcare system where decisions are routinely informed by personalized care profiles and predictive analytics, which will improve the health of individuals and populations.

Our mission

Deploy a versatile analytic platform that creates a shared understanding of quantified health risks to inform actions with the greatest potential to benefit patients.

Who we are

We collaborate with leading health systems and integrated delivery networks, value-based care and accountable care organizations, physician groups, and commercial payers to improve care delivery and population health while reducing costs and making efficient use of scarce clinical resources.

Phil Devlin
COO

Phil has 30 years of experience in executive leadership. Along his journey he’s made effective and profound change in science. Little known facts about him — he loves traveling with his family, he was in the MD Engineering program at Harvard Medical School and owns 15 patents. He received an MS from Northeastern University.